A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 171 in Subjects With Obesity
Latest Information Update: 25 Sep 2024
At a glance
- Drugs AMG 171 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Amgen
- 20 Dec 2021 Status changed from recruiting to discontinued.
- 02 Jun 2021 Planned End Date changed from 4 Aug 2021 to 27 Apr 2022.
- 02 Jun 2021 Planned primary completion date changed from 4 Aug 2021 to 27 Apr 2022.